Prelude Therapeutics PRLD Cash Flow Statement (2019-2026)

NASDAQ PRLD
$3.53 +0.14 (+4.13%)
At close: Oct 20, 2026 · 4:00 PM EDT
Reported Financials

Prelude Therapeutics Quarterly Cash Flow Statement

Periods 28 quarters
Latest Jun 2026

Prelude Therapeutics reported cash from operations of -$15.57M and free cash flow of -$15.57M for the quarter ended Jun 2026, up 40.3% year over year. This cash flow statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-30.69M-32.84M-29.47M-27.37M-29.96M-28.64M-27.72M-30.43M-30.61M-33.08M-31.43M-34.74M-32.27M-28.73M-32.09M-31.23M-19.73M-16.46M-10.39M-13.92M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.27M0.29M0.31M0.32M0.34M0.36M0.28M0.28M0.28M0.33M0.43M0.45M0.41M0.49M0.44M0.43M0.43M0.42M0.39M0.35M
Share-based CompensationStock Comp.
7.03M5.78M6.83M6.03M6.44M5.85M6.26M6.73M6.72M5.91M5.55M6.10M5.93M3.77M3.83M3.81M2.42M1.84M2.00M2.03M
Gains from Investment SecuritiesGains Investment
-0.54M-1.60M0.02M-0.07M0.67M1.29M-0.31M0.11M0.83M-0.46M-0.06M0.46M-0.13M-0.02M-0.01M0.00M0.01M-0.05M-0.19M
Other non-cash itemsOther Non-Cash
0.36M0.40M0.41M0.43M0.44M0.44M0.43M0.44M0.45M0.61M0.41M0.40M0.39M0.39M0.38M0.38M0.38M0.38M0.39M0.39M
Change in Working Capital
Change in Account PayablesChange Payables
4.51M-3.93M0.00M-0.84M3.73M-3.24M0.37M-1.71M-0.47M-0.47M0.63M1.08M-0.21M1.81M-1.91M-0.85M-2.43M1.27M-1.88M-0.15M
Change in Accured ExpensesChange Accured Exp.
0.46M2.86M-0.40M0.90M3.17M3.17M-1.90M-2.59M2.62M4.40M-5.69M1.23M2.09M1.57M-3.97M1.87M-0.37M-0.52M-6.60M1.92M
Change in Other Operating AssetsOther Assets Change
3.58M-1.15M-0.09M-1.46M5.15M0.25M0.36M2.19M-0.49M-1.76M0.79M-0.57M-0.11M-0.48M1.05M0.33M-0.29M-0.90M0.56M0.10M
Change in Other Operating LiabilitiesOther Liabilities Change
0.49M0.41M0.42M0.43M0.43M0.43M0.44M0.45M0.46M0.27M-0.64M2.81M-3.08M-0.14M-0.05M-0.05M0.06M35.60M-4.51M-5.63M
Other Working Capital ChangesOther WC Changes
-3.08M1.56M0.51M1.89M-4.71M0.18M0.09M-1.73M0.95M2.02M-1.43M3.38M-2.97M0.35M-1.10M-0.38M0.35M36.49M-5.07M-5.74M
Cash from OperationsCash from Ops.
-21.77M-25.70M-21.90M-18.47M-20.44M-22.93M-30.13M-27.67M-25.68M-23.58M-31.79M-23.06M-27.30M-20.74M-34.23M-26.08M-19.12M23.12M-21.69M-15.57M
Investing Activities
Capital ExpendituresCapex
0.66M0.30M0.95M0.76M0.92M0.39M0.81M0.98M0.59M1.13M0.29M0.36M0.06M0.05M0.05M0.02M
Change in Property, Plant and EquipmentChange in PP&E
-0.66M-0.30M-0.95M-0.76M-0.92M-0.39M-0.81M-0.98M-0.59M-1.13M-0.29M-0.36M-0.06M-0.05M-0.05M-0.02M
Purchase of InvestmentsInvestments Purchased
1.51M58.83M33.25M7.19M120.94M34.11M59.39M5.49M7.88M31.99M7.33M9.46M24.66M66.74M89.97M
Sale and Maturity of InvestmentsInvestments Sold
42.50M45.08M81.36M35.00M26.00M46.50M49.75M68.25M37.00M34.36M42.79M29.50M71.70M36.21M40.09M6.40M8.50M24.46M
Cash from Investing ActivitiesCash from Investing
-260.63M-1.80M0.15M58.58M21.61M1.36M18.00M-75.43M15.05M7.74M31.22M26.12M10.73M22.12M62.19M11.52M40.09M-60.34M8.50M-65.50M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment
0.15M0.15M0.16M0.05M
Non-Current Debt
-0.15M-0.15M-0.16M-0.05M
Net Debt Issuances and RepaymentsNet Debt Issuance
-0.15M-0.15M-0.16M-0.05M
Change in Capital Stock
Common Stock IssuedStock Issued
0.71M2.26M0.15M0.36M0.15M0.16M0.03M110.40M0.75M24.80M0.00M0.26M0.06M0.12M0.09M0.07M0.03M0.20M
Net Shares Issued and RepurchasedNet Shares Issued
0.71M2.26M0.15M0.36M0.15M0.16M0.03M110.40M0.75M24.80M0.00M0.26M0.06M0.12M0.09M0.07M0.03M0.20M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.71M2.26M0.15M0.36M0.15M0.16M0.03M110.40M0.75M24.80M0.00M0.26M0.06M0.12M0.09M0.07M0.03M0.20M
Other financing activitiesOther financing
-0.30M-2.60M2.88M-2.80M-0.02M-0.10M-0.04M-0.01M-0.01M0.00M-0.01M-0.01M-0.35M-4.38M
Cash from Financing ActivitiesCash from Financing
0.71M1.95M41.55M-41.04M0.15M0.16M-0.27M111.34M0.09M25.24M-0.01M0.06M-0.13M-0.03M-0.16M0.04M-0.01M24.94M-0.31M85.82M
Additional items
Change in Cash
-281.70M-25.55M19.81M-0.93M1.32M-21.42M-12.40M8.25M-10.55M9.40M-0.58M3.12M-16.69M1.34M27.80M-14.52M20.97M-12.28M-13.50M4.74M
Ending Cash Balance
61.42M35.87M55.68M54.75M56.07M34.65M22.25M30.49M19.94M29.34M28.75M31.87M15.18M16.52M44.31M29.80M50.77M38.49M24.99M29.73M
Free Cash FlowFCF
-22.43M-26.00M-22.85M-19.23M-21.36M-23.32M-30.94M-28.65M-26.27M-24.71M-32.08M-23.42M-27.36M-20.80M-34.28M-26.10M-19.12M23.12M-21.69M-15.57M
Net Cash FlowNCF
-281.70M-25.55M19.81M-0.93M1.32M-21.42M-12.40M8.25M-10.55M9.40M-0.58M3.12M-16.69M1.34M27.80M-14.52M20.97M-12.28M-13.50M4.74M

Prelude Therapeutics Cash Flow Statement API

Pull Prelude Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=PRLD&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY